ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt

Kassem, Amira B.; Salem, Salem Eid; Abdelrahim, Mohamed; Said, Amira S. A.; Salahuddin, A; Hussein, Marwa M.; Bahnassy, Abeer A.

doi:10.1016/j.yexmp.2017.01.006

Cited by 14 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[ 36 ]. Huang et al analyzed ERCC2 expression by immunohistochemistry in 180 colorectal cancer patients with adjuvant chemotherapy and showed that ERCC2 was not related to survival time; moreover, similar results were observed in a study by Kassem et al [ 8 , 37 ]. As far as GC is concerned, the prognosis associated with ERCC2 mRNA expression has not been reported.…”

Section: Discussionsupporting

confidence: 52%

Prognostic Value of Excision Repair Cross-Complementing mRNA Expression in Gastric Cancer

Luo

Liao

Zhu

2018

BioMed Research International

View full text Add to dashboard Cite

Except for excision repair cross-complementing 1 (ERCC1), mRNA expression of the remaining ERCC genes has not been investigated in the prognosis of gastric cancer (GC). The present study aimed to explore the mRNA expression and prognostic values of each member of the ERCC family in GC patients by using the Kaplan–Meier (KM) plotter tool. The details of each ERCC family member were entered into a database and GC patients were separated into high and low expression to draw survival plots using the KM plotter. In the present study, we observed that high expression of ERCC1 mRNA was significantly associated with longer overall survival (OS) for all GC patients (hazard ratio [HR]=0.77, 95% confidence intervals [CI]=0.63–0.95, P=0.016) compared with low expression. High expression of ERCC4 and ERCC6 mRNA indicated a worse OS for all GC patients (HR=1.28, 95% CI=1.02–1.6, P=0.035 and HR=1.25, 95% CI=1.02–1.54, P=0.029, respectively) and especially for patients with intestinal-type GC (HR=1.87, 95% CI=1.26–2.79, P=0.0018 and HR=1.62, 95% CI=1.04–2.54, P=0.033, respectively). High ERCC8 mRNA expression indicated a worse OS for all GC patients (HR=1.34, 95% CI=1.02–1.76, P=0.034) and especially for patients with diffuse-type GC (HR=2.25, 95% CI=1.36–3.75, P=0.0013). In conclusion, our findings indicate that ERCC4, ERCC6, and ERCC8 may be potential biomarkers for GC prognosis and may serve as potential therapeutic targets for GC. However, these findings still need further verification.

show abstract

Section: Discussionsupporting

confidence: 52%

Prognostic Value of Excision Repair Cross-Complementing mRNA Expression in Gastric Cancer

Luo

Liao

Zhu

2018

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Huang et al performed immunohistochemical staining of ERCC2 protein in 180 CRC patients but failed to construct relationship between ERCC2 and clinical outcome of CRC [ 32 ]. Another study carried out in 80 Egypt CRC patients detected both the mRNA and protein expressions of ERCC2 but found no significant relation between ERCC2 levels and OS or EFS (event free survival) [ 33 ]. In colon cancer, high expression of ERCC4 was associated with significantly favourable OS than those with low ERCC4 expression in males.…”

Section: Discussionmentioning

confidence: 99%

The Differential Expression of Core Genes in Nucleotide Excision Repair Pathway Indicates Colorectal Carcinogenesis and Prognosis

Liu

Sun

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

Background Nucleotide excision repair (NER) plays a critical role in maintaining genome integrity. This study aimed to investigate the expression of NER genes and their associations with colorectal cancer (CRC) development. Method Expressions of NER genes in CRC and normal tissues were analysed by ONCOMINE. The Cancer Genome Atlas (TCGA) data were downloaded to explore relationship of NER expression with clinicopathological parameters and survival of CRC. Results ERCC1, ERCC2, ERCC5, and DDB2 were upregulated while ERCC4 was downregulated in CRC. For colon cancer, high ERCC3 expression was related to better T stage; ERCC5 expression indicated deeper T stage and distant metastasis; DDB2 expression suggested earlier TNM stage. For rectal cancer, ERCC2 expression correlated with favourable T stage; XPA expression predicted worse TNM stage. ERCC2 expression was associated with worse overall survival (OS) in colon cancer (HR = 1.53, P = 0.043). Colon cancer patients with high ERCC4 expression showed favorable OS in males (HR = 0.54, P = 0.035). High XPC expression demonstrated decreased death hazards in rectal cancer (HR = 0.40, P = 0.026). Conclusion ERCC1, ERCC2, ERCC4, ERCC5, and DDB2 were differently expressed in CRC and normal tissues; ERCC2, ERCC3, ERCC5, XPA, and DDB2 correlated with clinicopathological parameters of CRC, while ERCC2, ERCC4, and XPC might predict CRC prognosis.

show abstract

“…However, the opposite association was observed in three studies (Lamas et al, 2011;Gan et al, 2012;Li et al, 2012), and five studies did not find significant associations with treatment outcome (Monzo et al, 2007;Martinez-Balibrea et al, 2008;Etienne-Grimaldi et al, 2010;Farina Sarasqueta et al, 2011;Huang et al, 2011). Lastly, one study assessed mRNA expression level of XPD for its association with treatment outcome, and no significant association was observed (Kassem et al, 2017).…”

Section: Xpd/ercc2mentioning

confidence: 95%

“…Both polymorphisms showed no significant association with treatment outcome. Moreover, two (Kassem et al, 2017;Rao et al, 2019) out of five (Basso et al, 2013;Li et al, 2014;Sfakianaki et al, 2019) studies based on mRNA or protein expression level of ERCC1 showed a significant association between low ERCC1 expression and prolonged PFS and OS.…”

Section: Ner Pathway Ercc1mentioning

confidence: 99%

Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

show abstract

ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt

Cited by 14 publications

References 26 publications

Prognostic Value of Excision Repair Cross-Complementing mRNA Expression in Gastric Cancer

Prognostic Value of Excision Repair Cross-Complementing mRNA Expression in Gastric Cancer

The Differential Expression of Core Genes in Nucleotide Excision Repair Pathway Indicates Colorectal Carcinogenesis and Prognosis

Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review

Contact Info

Product

Resources

About